<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32498636</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-7422</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>15-16</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Human gene therapy</Title><ISOAbbreviation>Hum Gene Ther</ISOAbbreviation></Journal><ArticleTitle>Intralingual Administration of AAVrh10-miR<sup><i>SOD1</i></sup> Improves Respiratory But Not Swallowing Function in a Superoxide Dismutase-1 Mouse Model of Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>828</StartPage><EndPage>838</EndPage><MedlinePgn>828-838</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/hum.2020.065</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal disease characterized by degeneration of motor neurons and muscles, and death is usually a result of impaired respiratory function due to loss of motor neurons that control upper airway muscles and/or the diaphragm. Currently, no cure for ALS exists and treatments to date do not significantly improve respiratory or swallowing function. One cause of ALS is a mutation in the superoxide dismutase-1 (<i>SOD1</i>) gene; thus, reducing expression of the mutated gene may slow the progression of the disease. Our group has been studying the <i>SOD1</i><sup>G93A</sup> transgenic mouse model of ALS that develops progressive respiratory deficits and dysphagia. We hypothesize that solely treating the tongue in <i>SOD1</i> mice will preserve respiratory and swallowing function, and it will prolong survival. At 6 weeks of age, 11 <i>SOD1</i><sup>G93A</sup> mice (both sexes) received a single intralingual injection of gene therapy (AAVrh10-miR<sup><i>SOD1</i></sup>). Another 29 mice (both sexes) were divided into two control groups: (1) 12 <i>SOD1</i><sup>G93A</sup> mice that received a single intralingual vehicle injection (saline); and (2) 17 non-transgenic littermates. Starting at 13 weeks of age, plethysmography (respiratory parameters) at baseline and in response to hypoxia (11% O<sub>2</sub>) + hypercapnia (7% CO<sub>2</sub>) were recorded and videofluoroscopic swallow study testing were performed twice monthly until end-stage disease. Minute ventilation during hypoxia + hypercapnia and mean inspiratory flow at baseline were significantly reduced (<i>p</i>&#x2009;&lt;&#x2009;0.05) in vehicle-injected, but not AAVrh10-miR<sup><i>SOD1</i></sup>-injected <i>SOD1</i><sup>G93A</sup> mice as compared with wild-type mice. In contrast, swallowing function was unchanged by AAVrh10-miR<sup><i>SOD1</i></sup> treatment (<i>p</i>&#x2009;&gt;&#x2009;0.05). AAVrh10-miR<sup><i>SOD1</i></sup> injections also significantly extended survival in females by &#x223c;1 week. In conclusion, this study indicates that intralingual AAVrh10-miR<sup><i>SOD1</i></sup> treatment preserved respiratory (but not swallowing) function potentially <i>via</i> increasing upper airway patency, and it is worthy of further exploration as a possible therapy to preserve respiratory capacity in ALS patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lind</LastName><ForeName>Lori A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Missouri, Columbia, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andel</LastName><ForeName>Ellyn M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, University of Missouri, Columbia, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCall</LastName><ForeName>Angela L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Duke University, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhindsa</LastName><ForeName>Justin S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Duke University, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Katherine A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Missouri, Columbia, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stricklin</LastName><ForeName>Olivia E</ForeName><Initials>OE</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Missouri, Columbia, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mueller</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, University of Massachusetts Medical School, Worcester Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>ElMallah</LastName><ForeName>Mai K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Duke University, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lever</LastName><ForeName>Teresa E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Missouri, Columbia, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology, University of Missouri, Columbia, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nichols</LastName><ForeName>Nicole L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Missouri, Columbia, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dalton Cardiovascular Research Center, University of Missouri, Columbia, Missouri, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K99 HL119606</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 HL119606</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 DC016071</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS098131</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Gene Ther</MedlineTA><NlmUniqueID>9008950</NlmUniqueID><ISSNLinking>1043-0342</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003679" MajorTopicYN="Y">Deglutition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="Y">Genetic Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012131" MajorTopicYN="N">Respiratory Insufficiency</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">breathing</Keyword><Keyword MajorTopicYN="N">gene therapy</Keyword><Keyword MajorTopicYN="N">neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">tongue</Keyword><Keyword MajorTopicYN="N">ventilation</Keyword></KeywordList><CoiStatement>No competing financial interests exist for L.A.L., E.M.A., A.L.M., K.A.J., O.E.S., M.K.E., T.E.L., and N.L.N. C.M. is a co-founder of Apic Bio. Apic Bio has licensed patents related to this work in which C.M. is an inventor.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32498636</ArticleId><ArticleId IdType="pmc">PMC7462029</ArticleId><ArticleId IdType="doi">10.1089/hum.2020.065</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. . Amyotrophic lateral sclerosis. Lancet 2011;377:942&#x2013;955</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Pradat PF, Salachas F, et al. . Causes of death in a post-mortem series of ALS patients. Amyotroph Lateral Scler 2008;9:59&#x2013;62</Citation><ArticleIdList><ArticleId IdType="pubmed">17924236</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurian KM, Forbes RB, Colville S, et al. . Cause of death and clinical grading criteria in a cohort of amyotrophic lateral sclerosis cases undergoing autopsy from the Scottish Motor Neurone Disease Register. J Neurol Neurosurg Psychiatry 2009;80:84&#x2013;87</Citation><ArticleIdList><ArticleId IdType="pubmed">19091712</ArticleId></ArticleIdList></Reference><Reference><Citation>Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci 2013;14:248&#x2013;264</Citation><ArticleIdList><ArticleId IdType="pubmed">23463272</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols NL, Van Dyke J, Nashold L, et al. . Ventilatory control in ALS. Respir Physiol Neurobiol 2013;189:429&#x2013;437</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4361018</ArticleId><ArticleId IdType="pubmed">23692930</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonardis L, Dolenc Groselj L, Vidmar G. Factors related to respiration influencing survival and respiratory function in patients with amyotrophic lateral sclerosis: a retrospective study. Eur J Neurol 2012;19:1518&#x2013;1524</Citation><ArticleIdList><ArticleId IdType="pubmed">22594630</ArticleId></ArticleIdList></Reference><Reference><Citation>Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867&#x2013;903</Citation><ArticleIdList><ArticleId IdType="pubmed">11934711</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair GB, Niederman MS. Ventilator-associated pneumonia: present understanding and ongoing debates. Intensive Care Med 2015;41:34&#x2013;48</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095124</ArticleId><ArticleId IdType="pubmed">25427866</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhnlein P, Gdynia HJ, Sperfeld AD, et al. . Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis. Nat Clin Pract Neurol 2008;4:366&#x2013;374</Citation><ArticleIdList><ArticleId IdType="pubmed">18560390</ArticleId></ArticleIdList></Reference><Reference><Citation>Strand EA, Miller RM, Yorkston KM, et al. . Management of oral-pharyngeal dysphagia symptoms in amyotrophic lateral sclerosis. Dysphagia 1996;11:129&#x2013;139</Citation><ArticleIdList><ArticleId IdType="pubmed">8721072</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleopa KA, Sherman M, Neal B, et al. . Bipap improves survival and rate of pulmonary function decline in patients with ALS. J Neurol Sci 1999;164:82&#x2013;88</Citation><ArticleIdList><ArticleId IdType="pubmed">10385053</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N. Disease status and use of ventilatory support by ALS patients. BDNF Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2:19&#x2013;22</Citation><ArticleIdList><ArticleId IdType="pubmed">11465928</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, Cleveland DW. Mechanisms of selective motor neuron death in ALS: insights from transgenic mouse models of motor neuron disease. Neuropathol Appl Neurobiol 1996;22:373&#x2013;387</Citation><ArticleIdList><ArticleId IdType="pubmed">8930947</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica L, Todeasa SH, Cabrera GT, et al. . Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann Neurol 2016;79:687&#x2013;700</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5374859</ArticleId><ArticleId IdType="pubmed">26891182</ArticleId></ArticleIdList></Reference><Reference><Citation>Borel F, Gernoux G, Cardozo B, et al. . Therapeutic rAAVrh10 mediated SOD1 silencing in adult SOD1(G93A) mice and nonhuman primates. Hum Gene Ther 2016;27:19&#x2013;31</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4741242</ArticleId><ArticleId IdType="pubmed">26710998</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, et al. . Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994;264:1772&#x2013;1775</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica L, Keeler AM, Xiong L, et al. . Restrictive lung disease in the Cu/Zn superoxide-dismutase 1 G93A amyotrophic lateral sclerosis mouse model. Am J Respir Cell Mol Biol 2017;56:405&#x2013;408</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5359540</ArticleId><ArticleId IdType="pubmed">28248134</ArticleId></ArticleIdList></Reference><Reference><Citation>Smittkamp SE, Brown JW, Stanford JA. Time-course and characterization of orolingual motor deficits in B6SJL-Tg(SOD1-G93A)1Gur/J mice. Neuroscience 2008;151:613&#x2013;621</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2244802</ArticleId><ArticleId IdType="pubmed">18061359</ArticleId></ArticleIdList></Reference><Reference><Citation>Tankersley CG, Haenggeli C, Rothstein JD. Respiratory impairment in a mouse model of amyotrophic lateral sclerosis. J Appl Physiol (1985) 2007;102:926&#x2013;932</Citation><ArticleIdList><ArticleId IdType="pubmed">17110520</ArticleId></ArticleIdList></Reference><Reference><Citation>Osman KL, Kohlberg S, Mok A, et al. . Optimizing the translational value of mouse models of ALS for dysphagia therapeutic discovery. Dysphagia 2020;35:343&#x2013;359</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6954990</ArticleId><ArticleId IdType="pubmed">31300881</ArticleId></ArticleIdList></Reference><Reference><Citation>Haenggeli C, Kato AC. Differential vulnerability of cranial motoneurons in mouse models with motor neuron degeneration. Neurosci Lett 2002;335:39&#x2013;43</Citation><ArticleIdList><ArticleId IdType="pubmed">12457737</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinsant S, Mansfield C, Jimenez-Moreno R, et al. . Characterization of early pathogenesis in the SOD1(G93A) mouse model of ALS: part I, background and methods. Brain Behav 2013;3:335&#x2013;350</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3869677</ArticleId><ArticleId IdType="pubmed">24381807</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinsant S, Mansfield C, Jimenez-Moreno R, et al. . Characterization of early pathogenesis in the SOD1(G93A) mouse model of ALS: part II, results and discussion. Brain Behav 2013;3:431&#x2013;457</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3869683</ArticleId><ArticleId IdType="pubmed">24381813</ArticleId></ArticleIdList></Reference><Reference><Citation>Lever TE, Gorsek A, Cox KT, et al. . An animal model of oral dysphagia in amyotrophic lateral sclerosis. Dysphagia 2009;24:180&#x2013;195</Citation><ArticleIdList><ArticleId IdType="pubmed">19107538</ArticleId></ArticleIdList></Reference><Reference><Citation>Lever TE, Simon E, Cox KT, et al. . A mouse model of pharyngeal dysphagia in amyotrophic lateral sclerosis. Dysphagia 2010;25:112&#x2013;126</Citation><ArticleIdList><ArticleId IdType="pubmed">19495873</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C, Ratner D, Zhong L, et al. . Production and discovery of novel recombinant adeno-associated viral vectors. Curr Protoc Microbiol 2012;Chapter 14:Unit14D 11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4358842</ArticleId><ArticleId IdType="pubmed">22875565</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhury SR, Fitzpatrick Z, Harris AF, et al. . In vivo selection yields AAV-B1 capsid for central nervous system and muscle gene therapy. Mol Ther 2016;24:1247&#x2013;1257</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5088762</ArticleId><ArticleId IdType="pubmed">27117222</ArticleId></ArticleIdList></Reference><Reference><Citation>ElMallah MK, Falk DJ, Lane MA, et al. . Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9. Hum Gene Ther Methods 2012;23:148&#x2013;156</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4015220</ArticleId><ArticleId IdType="pubmed">22693957</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmallah MK, Falk DJ, Nayak S, et al. . Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice. Mol Ther 2014;22:702&#x2013;712</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3982493</ArticleId><ArticleId IdType="pubmed">24336173</ArticleId></ArticleIdList></Reference><Reference><Citation>Lever TE, Braun SM, Brooks RT, et al. . Adapting human videofluoroscopic swallow study methods to detect and characterize dysphagia in murine disease models. J Vis Exp 2015;97:52319</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4401177</ArticleId><ArticleId IdType="pubmed">25866882</ArticleId></ArticleIdList></Reference><Reference><Citation>Lever TE, Brooks RT, Thombs LA, et al. . Videofluoroscopic validation of a translational murine model of presbyphagia. Dysphagia 2015;30:328&#x2013;342</Citation><ArticleIdList><ArticleId IdType="pubmed">25783697</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeler AM, Zieger M, Todeasa SH, et al. . Systemic delivery of AAVB1-GAA clears glycogen and prolongs survival in a mouse model of pompe disease. Hum Gene Ther 2019;30:57&#x2013;68</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6343199</ArticleId><ArticleId IdType="pubmed">29901418</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402&#x2013;408</Citation><ArticleIdList><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfohl SR, Halicek MT, Mitchell CS. Characterization of the contribution of genetic background and gender to disease progression in the SOD1 G93A mouse model of amyotrophic lateral sclerosis: a meta-analysis. J Neuromuscul Dis 2015;2:137&#x2013;150</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4652798</ArticleId><ArticleId IdType="pubmed">26594635</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed RM, Newcombe RE, Piper AJ, et al. . Sleep disorders and respiratory function in amyotrophic lateral sclerosis. Sleep Med Rev 2016;26:33&#x2013;42</Citation><ArticleIdList><ArticleId IdType="pubmed">26166297</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuller D, Mateika JH, Fregosi RF. Co-activation of tongue protrudor and retractor muscles during chemoreceptor stimulation in the rat. J Physiol 1998;507(Pt. 1):265&#x2013;276</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2230762</ArticleId><ArticleId IdType="pubmed">9490849</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos C, Braghiroli A, Mazzini L, et al. . Sleep-related breathing disorders in amyotrophic lateral sclerosis. Monaldi Arch Chest Dis 2003;59:160&#x2013;165</Citation><ArticleIdList><ArticleId IdType="pubmed">14635507</ArticleId></ArticleIdList></Reference><Reference><Citation>Atalaia A, De Carvalho M, Evangelista T, et al. . Sleep characteristics of amyotrophic lateral sclerosis in patients with preserved diaphragmatic function. Amyotroph Lateral Scler 2007;8:101&#x2013;105</Citation><ArticleIdList><ArticleId IdType="pubmed">17453638</ArticleId></ArticleIdList></Reference><Reference><Citation>Greig JA, Calcedo R, Grant RL, et al. . Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques. Vaccine 2016;34:6323&#x2013;6329</Citation><ArticleIdList><ArticleId IdType="pubmed">27817961</ArticleId></ArticleIdList></Reference><Reference><Citation>Greig JA, Peng H, Ohlstein J, et al. . Intramuscular injection of AAV8 in mice and macaques is associated with substantial hepatic targeting and transgene expression. PLoS One 2014;9:e112268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4230988</ArticleId><ArticleId IdType="pubmed">25393537</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YJ, Gao CY, Yang M, et al. . Intramuscular delivery of a single chain antibody gene prevents brain Abeta deposition and cognitive impairment in a mouse model of Alzheimer's disease. Brain Behav Immun 2010;24:1281&#x2013;1293</Citation><ArticleIdList><ArticleId IdType="pubmed">20595065</ArticleId></ArticleIdList></Reference><Reference><Citation>Flotte TR, Conlon TJ, Poirier A, et al. . Preclinical characterization of a recombinant adeno-associated virus type 1-pseudotyped vector demonstrates dose-dependent injection site inflammation and dissemination of vector genomes to distant sites. Hum Gene Ther 2007;18:245&#x2013;256</Citation><ArticleIdList><ArticleId IdType="pubmed">17376008</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertekin C, Aydogdu I. Neurophysiology of swallowing. Clin Neurophysiol 2003;114:2226&#x2013;2244</Citation><ArticleIdList><ArticleId IdType="pubmed">14652082</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw SM, Martino R. The normal swallow: muscular and neurophysiological control. Otolaryngol Clin North Am 2013;46:937&#x2013;956</Citation><ArticleIdList><ArticleId IdType="pubmed">24262952</ArticleId></ArticleIdList></Reference><Reference><Citation>Weikamp JG, Schelhaas HJ, Hendriks JC, et al. . Prognostic value of decreased tongue strength on survival time in patients with amyotrophic lateral sclerosis. J Neurol 2012;259:2360&#x2013;2365</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3484270</ArticleId><ArticleId IdType="pubmed">22527240</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmore SE, Lehman ME. Physiologic deficits in the orofacial system underlying dysarthria in amyotrophic lateral sclerosis. J Speech Hear Res 1994;37:28&#x2013;37</Citation><ArticleIdList><ArticleId IdType="pubmed">8170127</ArticleId></ArticleIdList></Reference><Reference><Citation>da Costa Franceschini A, Mourao LF. Dysarthria and dysphagia in Amyotrophic Lateral Sclerosis with spinal onset: a study of quality of life related to swallowing. NeuroRehabilitation 2015;36:127&#x2013;134</Citation><ArticleIdList><ArticleId IdType="pubmed">25547774</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers KJ, Anthony DC, Randolph GW, et al. . Atrophy of the tongue following complete versus partial hypoglossal nerve transection in a canine model. Laryngoscope 2016;126:2689&#x2013;2693</Citation><ArticleIdList><ArticleId IdType="pubmed">27271961</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjikoutis S, Wiles CM. Respiratory complications related to bulbar dysfunction in motor neuron disease. Acta Neurol Scand 2001;103:207&#x2013;213</Citation><ArticleIdList><ArticleId IdType="pubmed">11328190</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonduelle M. Amyotrophic lateral sclerosis. Handbook Clin Neurol 1975;22:281&#x2013;347</Citation></Reference><Reference><Citation>DePaul R, Abbs JH, Caligiuri M, et al. . Hypoglossal, trigeminal, and facial motoneuron involvement in amyotrophic lateral sclerosis. Neurology 1988;38:281&#x2013;283</Citation><ArticleIdList><ArticleId IdType="pubmed">3340294</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes JT. Pathology of amyotrophic lateral sclerosis. Adv Neurol 1982;36:61&#x2013;74</Citation><ArticleIdList><ArticleId IdType="pubmed">7180695</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawyer T Jr., Netsky MG. Amyotrophic lateral sclerosis. AMA Arch Neurol Psychiatry 1953;69:171&#x2013;192</Citation><ArticleIdList><ArticleId IdType="pubmed">13007227</ArticleId></ArticleIdList></Reference><Reference><Citation>Gourie-Devi M, Nalini A, Sandhya S. Early or late appearance of &#x201c;dropped head syndrome&#x201d; in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2003;74:683&#x2013;686</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738454</ArticleId><ArticleId IdType="pubmed">12700323</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins KL, Allen MJ, Lever TE. Low copy number SOD1-G93A mice are better suited for dysphagia research compared to the high copy number model. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:217&#x2013;226</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>van Zundert B, Brown RH Jr. Silencing strategies for therapy of SOD1-mediated ALS. Neurosci Lett 2017;636:32&#x2013;39</Citation><ArticleIdList><ArticleId IdType="pubmed">27507699</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Yang B, Mu X, et al. . Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther 2011;19:1440&#x2013;1448</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149178</ArticleId><ArticleId IdType="pubmed">21610699</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaspar BK, Erickson D, Schaffer D, et al. . Targeted retrograde gene delivery for neuronal protection. Mol Ther 2002;5:50&#x2013;56</Citation><ArticleIdList><ArticleId IdType="pubmed">11786045</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, Hu H, Duan W, et al. . Intramuscular Delivery of scAAV9-hIGF1 prolongs survival in the hSOD1(G93A) ALS mouse model via upregulation of D-amino acid oxidase. Mol Neurobiol 2018;55:682&#x2013;695</Citation><ArticleIdList><ArticleId IdType="pubmed">27995572</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaspar BK, Llado J, Sherkat N, et al. . Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003;301:839&#x2013;842</Citation><ArticleIdList><ArticleId IdType="pubmed">12907804</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeler AM, Zieger M, Semple C, et al. . Intralingual and intrapleural AAV gene therapy prolongs survival in a SOD1 ALS mouse model. Mol Ther Methods Clin Dev 2020;17:246&#x2013;257</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6962641</ArticleId><ArticleId IdType="pubmed">31970202</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>